Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11942
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bladin, Peter F | en |
dc.date.accessioned | 2015-05-16T01:34:34Z | - |
dc.date.available | 2015-05-16T01:34:34Z | - |
dc.date.issued | 2013-08-29 | en |
dc.identifier.citation | Journal of Clinical Neuroscience 2013; 21(1): 33-9 | en |
dc.identifier.govdoc | 24238829 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11942 | en |
dc.description.abstract | The well-established medical involvement of derivatives of the azo dye industry lent credibility to the 1935 announcement by Stanley Cobb of the use of vital brilliant red dye as an anticonvulsant. Although in the fullness of time clinical experience would discard this concept, nevertheless it was to give rise to Robert Aird who posited that the mechanism of action of this dye was due to its ability to decrease the permeability of the blood-brain barrier. In a very prolonged exploration of this concept, Aird concluded that blood-brain barrier permeability underlay the causation of a long list of chronic neurological conditions--a concept that was eventually abandoned. This article examines the details and the effects of this concept and its impact upon neurology. | en |
dc.language.iso | en | en |
dc.subject.other | Anticonvulsants | en |
dc.subject.other | Azo dyes | en |
dc.subject.other | Blood–brain barrier | en |
dc.subject.other | Chronic neurological condition | en |
dc.subject.other | Animals | en |
dc.subject.other | Anticonvulsants.pharmacology | en |
dc.subject.other | Azo Compounds.history.pharmacology | en |
dc.subject.other | Blood-Brain Barrier.drug effects | en |
dc.subject.other | Coloring Agents.history.pharmacology | en |
dc.subject.other | Epilepsy.drug therapy.etiology.physiopathology | en |
dc.subject.other | History, 20th Century | en |
dc.subject.other | History, 21st Century | en |
dc.subject.other | Humans | en |
dc.subject.other | United States | en |
dc.title | Azo dyes and the blood-brain barrier: Robert Aird's novel concept in chronic neurological disease (1903-2000). | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Journal of Clinical Neuroscience | en |
dc.identifier.affiliation | Comprehensive Epilepsy Program, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.doi | 10.1016/j.jocn.2013.06.014 | en |
dc.description.pages | 33-9 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/24238829 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Bladin, Peter F | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Neurology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.